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Background: Coronary artery disease (CAD) is the leading cause of death among individuals with type 2 diabetes
(T2DM). T2DM accelerates atherosclerosis alongside classical risk factors such as dyslipidemia and hypertension. This
study aims to investigate the association of hyperglycemia and associated risk factors with CAD in outpatients with
T2DM undergoing coronary angiography.
Methods: 818 individuals referred to coronary angiography were evaluated for glucose disturbances. After
exclusion of those with prediabetes, 347 individuals with T2DM and 94 normoglycemic controls were studied for
BMI, blood pressure, fasting plasma glucose, HbA1c, lipids, HOMA, adiponectin, Framingham risk score, number of
clinically significant coronary lesions (stenosis > 50%).
Results: Among T2DM subjects, those with CAD (n = 237) had worse glycemic control (fasting glucose 162.3 + 69.8
vs. 143.4 + 48.9 mg/dL, p = 0.004; HbA1c 8.03 + 1.91 vs. 7.59 + 1.55%, p = 0.03), lower HDL (39.2 + 13.2 vs. 44.4 +
15.9 mg/dL, p = 0.003), and higher triglycerides (140 [106–204] vs. 121 [78.5-184.25] mg/dL, p = 0.002), reached more
often therapeutic goals for LDL (63.4% vs. 51.4%, p = 0.037) and less often goals for HDL (26.6% vs. 37.3%, p = 0.04),
when compared to CAD-free individuals (n = 110). The same differences were not seen in normoglycemic controls.
In T2DM subjects HbA1c tertiles were associated with progressively higher number of significant coronary lesions
(median number of lesions 2 [A1c < 6.8%]; 2.5 [A1c 6.8-8.2%]; 4 [A1c > 8.2%]; p = 0.01 for trend).
Conclusions: Classic risk factors such as glycemic control and lipid profile were associated with presence of CAD in
T2DM subjects undergoing coronary angiography. Glycemic control is progressively associated with number and
extent of coronary lesions in patients with T2DM.
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Cardiovascular disease (CVD) accounts for up to 80% of
deaths in individuals with type 2 diabetes (T2DM) [1].
T2DM patients have a threefold higher risk than nondia-
betic individuals of developing atherosclerosis and its
clinical complications, such as stroke, myocardial infarc-
tion (MI), and peripheral vascular disease [2-5]. Acceler-
ation of atherosclerosis in these patients can be due to* Correspondence: andrefreis@terra.com.br
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article, unless otherwise stated.insulin deficiency, defective insulin action, and hypergly-
cemia or associated metabolic defects [6]. Arterial hyper-
tension and dyslipidemia frequently coexist with
diabetes and contribute to the increased prevalence of
CVD in diabetic patients [7-9]. The impact of some of
these metabolic factors may be amplified by the presence
of hyperglycemia. However, T2DM is regarded as an in-
dependent risk factor for cardiovascular disease [10].
The presence of hyperglycemia favors atherosclerosis
and imparts an increased risk of coronary artery disease
(CAD), even though the molecular mechanisms respon-
sible for this process are largely unknown [11]. Since
there are patients with T2DM that do not develop CAD,tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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CAD risk. Besides classical risk factors, interest has also
been drawn to other measurable factors that could im-
prove CAD risk assessment for T2DM patients, such as
adiponectin and high-sensitivity C-Reactive Protein
(hsCRP), among others [12]. The importance of identify-
ing risk factors unique to CAD patients with T2DM is to
control specific threats and outline goals, allowing more
targeted preventive measures, thus reducing their mor-
bidity and mortality.
Among various clinical strategies for CVD risk stratifi-
cation and dynamic cardiac tests for the identification of
vascular lesions, coronary angiography has a special role.
Despite being an invasive procedure, it’s a gold-standard
method allowing an objective analysis of the presence of
atherosclerosis, its extent, and severity.
The aim of this study was to investigate the association
of hyperglycemia and cardiovascular risk factors with
CAD diagnosed by coronary angiography in individuals
with T2DM and normoglycemia.
Methods
A total of 818 consecutive outpatients undergoing coron-
ary angiography at the Coronary Angiography Sector of
UNIFESP University Hospital (Hospital São Paulo) have
been studied. Patients were referred to the exam by their
physicians for various reasons, including presence of
stable angina, a positive stress test, clinical suspicion of
acute coronary syndrome, or for preoperative evaluation
of cardiac valvular disease or peripheral vascular disease
surgeries. Clinical data, as well as personal and familial
history of cardiovascular disease, diabetes mellitus and as-
sociated diseases, and medication use, were obtained by
an interviewer. Patients were examined for weight, height,
abdominal circumference, and blood pressure by a mem-
ber of the research group. We excluded from the study pa-
tients with impaired renal function (estimated by the
Modification of Diet in Renal Disease study equation, im-
paired renal function defined as MDRD< 50 ml/m2) [13],
altered thyroid function, active inflammatory disease, can-
cer, and confirmed acute coronary syndromes. Patients
with acute coronary syndromes and ST segment elevation
have been excluded because thrombotic events could
overestimate stenosis. Presence of T2DM was defined as
previous history of diabetes mellitus (diagnosed after
40 years old) or by American Diabetes Association criteria
[14]. We analyzed a subgroup of normoglycemic patients,
defined by meeting all the following criteria: absence of
personal history of diabetes mellitus, no use of antidiabetic
medication, and no newly diagnosed diabetes (HbA1c <
5,7% and < 100 mg/dL) at recruitment, to investigate dif-
ferences between individuals with or without CAD in the
absence of hyperglycemia, regarding risk factors and clin-
ical parameters. Presence of CAD was defined by anyvisible stenosis greater than 50% on angiography in at least
one major coronary artery or branch. Arterial hyper-
tension was defined as systolic blood pressure (SBP) ≥
140 mmHg and/or diastolic blood pressure (DBP) ≥
90 mmHg and/or antihypertensive medication use. Sub-
jects were considered to have dyslipidemia if they met any
of the following criteria: LDL-cholesterol ≥ 160 mg/dL,
HDL-cholesterol < 40 mg/dL, triglycerides ≥ 200 mg/dL,
or use of lipid lowering drugs (statins/fibrates) [15].
A blood sample was drawn after an overnight fast for
analysis of fasting plasma glucose (FPG), plasma insulin,
HbA1c (HPLC), lipid profile, TSH, and creatinine. The
homeostasis model assessment of insulin resistance
(HOMA-2IR) and β-cell function (HOMA-2B) [16] were
calculated using glucose and insulin levels. We excluded
from these analyses T2DM subjects using sulfonyulreas
and/or insulin. Total adiponectin was measured in plasma
samples using commercial ELISA kits (EZHADP-61 K,
Millipore, Saint Charles, MO). Intra- and inter-assay coef-
ficients of variation were respectively 7.4% and 10.6% (sen-
sitivity of 0.78 ng/mL). Individuals were assessed for
attaining treatment goal of major cardiovascular risk fac-
tors: blood pressure below 140 × 80 mmHg; HbA1c below
7%; LDL below 100 mg/dL (2.6 mmol/L); triglycerides
below 150 mg/dL (1.7 mmol/L); HDL above 40 mg/dL
(1.0 mmol/L) in men and 50 mg/dL (1.3 mmol/L) in
women [14].
The Framingham score was calculated as described
elsewhere [17]. In brief, gender, age, LDL-cholesterol,
HDL-cholesterol, systolic and diastolic blood pressure,
presence of diabetes mellitus, and current smoking sta-
tus were used to calculate the 10-year risk of CAD. Indi-
viduals with calculated risk above 20% were considered
as high risk for coronary events [18]. All participants
gave written informed consent. The study was approved
by the ethics committee of UNIFESP.
Results of continuous variables are expressed as mean ±
SD for normally distributed variables and median [inter-
quartile range] for those without normal distribution. Re-
sults of categorical variables are expressed as percentages.
Comparisons of anthropometric, clinical, and laboratory
phenotypes between groups were assessed by t-test and
Fisher’s exact test. For all analyses, data were log trans-
formed when the normality of distribution was rejected by
the Shapiro-Wilk W test. The number of significant cor-
onary lesions each in HbA1c tertile was analyzed by
Jonckheere-Terpstra test. A p value for trend was reported
in this case. Values of p < 0.05 were considered significant.
Statistical analyses were performed with the SPSS 13.0 for
Windows software (SPSS Inc., Chicago, IL, USA).
Results
From a total of 818 patients who underwent coronary
angiography, we identified 347 subjects with T2DM (54%
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(26.5%) were newly diagnosed. CAD was detected in
68.3% of T2DM patients. T2DM subjects with CAD
(n = 237), as compared to those without CAD (n = 110),
were older (61.6 vs. 59.1 years; p = 0.03) and more often
male (61.2 vs. 40%; p < 0.001) and had lower BMI (28.0 ±
4.4 vs. 29.2 ± 5.3 kg/m2; p = 0.04). Additionally, they
showed a worse metabolic profile with significantly higher
HbA1c, FPG, and triglyceride levels and lower HDL-
cholesterol (Table 1). T2DM patients with CAD were
more frequent users of statins (72.6% vs. 60.9%; p = 0.03),
even though the prevalence of dyslipidemia (~80%) was
similar between groups. Presence of hypertension, 94.5%
and 95.5%, was also similar between groups with andTable 1 Clinical and laboratory features of patients with diab
presence of CAD
Normoglycemic individuals
Without CAD With DAC
N 40 54
Age (years) 55.8 (12.9) 60.2 (13.6)
Male gender (%) 53.7 76.4
BMI (kg/m2) 27.1 (5.24) 26.4 (4.91)
Abdominal circumference (cm) 95.5 (12.9) 97.0 (12.4)
Diabetes duration (years)* – –
SBP (mmHg) 134.4 (21.8) 131.9 (22.6)
DBP (mmHg) 79.0 (15.4) 79.7 (14.2)
FPG (mg/dl) 90.4 (6.8) 90.8 (7.1)
Fasting insulin (mU/L) 6.44 (4.38) 6.10 (4.77)
HOMA2B 69.17 (25.63) 66.50 (25.82
HOMA2-IR 0.70 (0.41) 0.66 (0.42)
HbA1c (%) 5.28 (0.27) 5.35 (0.25)
LDL (mg/dL) 105.0 (34.8) 98.6 (33.4)
HDL (mg/dL) 42.7 (11.4) 38.4 (10.340
Triglycerides (mg/dL)* 116.0 [75.25-158.0] 115.0 [93.0-158
Total Adiponectin (μg/mL)* 11.80 [6.85-18.62] 8.73 [5.95-14.8
eGFR (mL/min) 88.1 (22.3) 83.6 (21.4)
Hypertension (%) 73.2 72.7
Framingham risk above 20% (%) 8.6 17
Statin use (%) 41.5 56.4
Aspirin use (%) 58.5 67.3
Diabetes treatment
Insulin (%) – –
Sulphonylurea (%) – –
Metformin (%) – –
Dyslipidemia (%) 70.7 89.1
Familial history of CAD (%) 29.3 45.5
Values expressed in mean (SD), except where otherwise noted; *values expressed in
with and without CAD, within diabetic and normoglycemic groups.without CAD respectively. Other known classical and
non-classical risk factors, such as SBP, DBP and LDL-
cholesterol, renal function estimated by MDRD, and adi-
ponectin levels were not different between groups. Dia-
betes duration and family history for CAD were also
similar between groups (Table 1). We observed a Framing-
ham Risk Score greater than 20% in 32.5% of patients with
CAD and 21.6% in the CAD negative group (p = 0.047).
No differences were noted in insulin resistance/secretion
surrogates such as HOMA-2IR, abdominal circumference,
and HOMA-2B.
Ninety-four normoglycemic individuals were detected in
our sample (66% male; mean age 58.3 ± 13.4 years old).
CAD was present in 57.4% of them. In this subgroup ofetes and normal glucose tolerance, according to the
Diabetic individuals
p** Without CAD With CAD p**
110 237
NS 59.1 (10.2) 61.6 (9.8) 0.03
0.02 40 61.2 0.001
NS 29.2 (5.32) 28.0 (4.40) 0.04
NS 101.9 (12.65) 100.5 (12.00) NS
– 4 [1-10] 6 [2-10] NS
NS 145.2 (24.6) 142.3 (24.6) NS
NS 82.4 (16.1) 79.2 (12.1) NS
NS 143.4 (48.9) 162.3 (69.8) 0.004
NS 14.6 (17.6) 10.9 (8.91) NS
) NS 75.56 (51.83) 64.07 (48.51) NS
NS 1.84 (1.67) 1.54 (1.03) NS
NS 7.59 (1.55) 8.03 (1.91) 0.03
NS 101.0 (39.9) 98.1 (36.2) NS
NS 44.4 (15.9) 39.2 (13.2) 0.003
.0] NS 121.0 [78.5-184.25] 140.0 [106.0-204.0] 0.002
8] NS 8.26 [5.49-12.86] 7.36 [5.33-11.83] NS
NS 83.1 (28.3) 80.4 (24.2) NS
NS 95.5 94.5 NS
NS 21.6 32.5 0.047
NS 60.9 72.6 0.03
NS 70 79.7 0.046
– 24.5 28.3 NS
– 20.4 27 NS
– 44.5 45.6 NS
0.023 89.1 90.3 NS
NS 34.9 35 NS
median [interquartile range]; **p values for comparisons between individuals
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53.7%; p = 0.02) and had higher frequency of dyslipidemia
(89.1% vs. 70.7%; p = 0.02) when compared to CAD-free
individuals (Table 1), but both groups of normoglycemic
individuals were similar in every other parameter, includ-
ing use of statins and other medication (data not shown).
Regarding fulfillment of therapeutic goals for dyslipid-
emia and hypertension in normoglycemic individuals, no
differences were observed between those with and with-
out CAD. Among individuals with T2DM, those with
CAD met therapeutic goals for LDL more frequently
than those without CAD (63.4% vs. 51,4%; p = 0.04) and
for HDL less frequently (26.6% vs. 37.3%; p = 0.04)
(Table 2).
We further stratified the 347 individuals with T2DM in
FPG and HbA1c tertiles and looked at the number of sig-
nificant coronary lesion (stenosis greater than 50% on
angiography), as a parameter to verify the extent and se-
verity of visible coronary disease. Median of coronary le-
sions were progressively higher in each HbA1c tertile
(2 vs. 2.5 vs. 4; p = 0.011 for trend) (Figure 1). Similar find-
ings were observed for FPG tertiles (data not shown).
Stratification of individuals by other parameters such as
triglycerides and HDL didn’t show significant association
with severity or number of coronary lesions (data not
shown). The same tertile analysis performed on normogly-
cemic individuals did not show any significant differences.
Discussion
We have studied the clinical and laboratory characteris-
tics of Brazilian T2DM patients with and without CAD
identified by coronary angiography. In this population of
T2DM subjects, some of the classical risk factors such
as age, glycemic control, HDL and triglyceride levels
were associated with the presence of CAD.
Glycemic control, measured by either fasting glucose
or HbA1c, was associated with CAD among T2DM pa-
tients. Moreover, both glucose and HbA1c levels were
associated with number of coronary lesions and severity
of stenosis (Figure 1). Our results reinforce the concept
that glycemic control plays a pivotal role in the presenceTable 2 Proportion of individuals meeting treatment goals fo
and blood pressure, according to the presence of CAD
Diabetic individuals
Without CAD With CAD
N 110 237
Blood pressure (%) 26.9 36.5
HbA1c (%) 45.5 40.9
LDL (%) 51.4 63.4
Triglycerides (%) 63.6 54.1
HDL (%) 37.3 26.6and extension of CAD, at least in this subgroup of
T2DM patients with high cardiovascular risk [6]. Even in
non-diabetic individuals HbA1c can be associated with
CAD and its severity [19], but this has not occurred in
our sample of normoglycemic individuals. In this regard,
there is some evidence from prospective studies that
more intensive treatment of blood glucose in newly di-
agnosed T2DM patients may reduce long-term CVD
rates. For instance, in the UKPDS trial, a 16% reduction
in cardiovascular events in the intensive glycemic con-
trol arm was noted, but did not reach statistical signifi-
cance. However, after 10 years of follow-up, patients
originally randomized to intensive glycemic control
showed a significant long-term reductions in MI [20],
underpinning the concept of metabolic memory in this
setting. Furthermore, more recent large trials [21-23]
suggested no significant reduction in CVD, or even a
higher risk of death, with intensive glycemic control in
patients who had more advanced T2DM as compared to
those on UKPDS. In the ACCORD Study, tight control
did not yield protection against CVD, mainly in those
with very long duration of diabetes, known history of se-
vere hypoglycemia, and advanced atherosclerosis. Of
note, all these trials were conducted in participants with
more long-standing T2DM (mean duration 8–11 years)
and either known CVD or multiple cardiovascular risk
factors [24]. For example, the ACCORD trial involved
persons who had had T2DM for a median of 10 years
[21]. In our study, especially study design and sample
characteristics differed markedly from ACCORD, the
most striking clinical distinction being diabetes duration,
roughly twice as much in ACCORD as in our sample.
Moreover, the latter studied a population with several
other risk factors and higher BMI.
We do not have information about the history of
metabolic control of our patients particularly in the first
years of disease, this period being probably important in
the metabolic memory of these individuals. This fact
limits a more in-depth analysis of metabolic control evo-
lution and CAD prevalence. In our sample, diabetes dur-
ation, a well-defined risk factor for both micro andr diabetes (HbA1c), lipids (HDL, LDL, and triglycerides),
Normoglycemic individuals
p Without CAD With CAD p
40 54
NS 32.4 43.1 NS
NS – –
0.037 46.2 56.9 NS
NS 72.5 73.6 NS
0.044 35.9 28.3 NS
1st (<6.8%) 2nd (6.8-8.2%) 3rd (>8.2%)
0
1
2
3
4
5
6
HbA1c tertiles
p=0.011 (for trend)
Figure 1 Box-and-whisker plot of the number of significant coronary lesion (stenosis greater than 50%) per patient, according to
HbA1c tertiles.
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individuals with and without CAD. This finding could
possibly derive from a hypothetically higher frequency of
newly diagnosed T2DM among individuals with CAD.
Nevertheless, both subgroups (with and without CAD)
had a similar proportion of novel cases of T2DM (data
not shown). Another possible explanation could be the
relatively short median diabetes duration in our sample
(~5 years). In this regard, some studies suggest that risk
for CAD starts to rise significantly after about 8 years of
diabetes evolution [1,25].
Dyslipidemia is a well-established risk factor for CAD
in different populations, with and without diabetes mel-
litus [26]. In our high risk group, approximately 80% of
patients had dyslipidemia. Low levels of HDL choles-
terol, often associated with elevated triglyceride levels,
are the most prevalent pattern of dyslipidemia in per-
sons with T2DM [14]. Both alterations were more preva-
lent in T2DM with CAD in our group. This lipid
modification is commonly associated with insulin resist-
ance [27,28]. However, we found no differences between
HOMA-IR between the groups. It is noteworthy that the
HOMA-IR in patients with T2DM was much higher
when compared to normoglycemic individuals, in agree-
ment with the role of insulin resistance in T2DM
(Table 1). If elevated LDL-cholesterol is a well defined
causal risk factor for CAD, uncertainty exists about
whether elevated triglyceride levels represents an add-
itional independent CVD risk factor [25]. Of course, data
from these epidemiological studies do not necessarilymean that triglycerides are not causally related to vascu-
lar risk. They could, however, be rather a marker of
metabolic disturbances than a causative factor of athero-
sclerosis such as HDL and glycemic control [25]. We did
not find any difference in LDL levels, but a higher rate
of statin users in patients with CAD was seen. Besides,
LDL targets for diabetic individuals could be even lower
than 100 mg/dL [14]. Our data show association of
worse HDL levels with CAD in diabetic individuals.
However, our study design precludes any assumption of
causal association. Moreover, adequately designed stud-
ies (prospective clinical trials) to evaluate the isolated
role of HDL in the diabetic population are unavailable.
Hypertension, likewise, is a well-known risk factor for
CAD [29]. In our study, there was no difference in fre-
quency of hypertension and either DBP or SBP levels in
diabetic individuals with or without CAD. Interestingly,
we did not find association of two known cardiovascular
risk factors, hypertension and elevated LDL levels, with
CAD. Since the majority of our study group had both
abnormalities (more than 80%), along with a high pro-
portion of users of medication to treat these risk factor,
our analyses could be unable to detect these differences.
Among T2DM individuals, there was a higher propor-
tion of CAD individuals having Framingham risk above
20%, as compared to CAD-free individuals, with a nom-
inally significant difference. Since our sample is com-
posed of high risk individuals (outpatients referred
to coronary angiography), this could possibly explain
the small difference between subgroups. Likewise,
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30%) [18] in both groups could derive from the same
fact. This could further contribute to blunt the differ-
ence between subgroups. Moreover, the validity of the
score in this scenario of high risk and prevalence of
overt CAD for predicting future coronary events could
be questioned, since it has not been designed with this
goal. Framingham risk score was not different between
individuals with and without CAD in the normoglycemic
group.
In the group of subjects with T2DM we observed a
lower BMI in CAD positive subjects. This result should
be viewed with extreme caution due to the only nominal
difference and also to the fact that it was an observa-
tional study. The issue of weight and cardiovascular
mortality in T2DM has been subject of intense discus-
sion recently after the publication of the Look AHEAD
study, which demonstrated that an intensive lifestyle
intervention focusing on weight loss did not reduce the
rate of cardiovascular events in overweight or obese
adults with T2DM [30]. Weight loss may also occur
from poor glycemic control, and therefore any beneficial
effects of weight loss in those who intentionally lost
weight are not distinguishable [31]. Recent evidence has
shown that while the risk of mortality increases at higher
BMIs at the time of T2DM diagnosis, there is also a
higher risk of mortality for those diagnosed at a lower
BMI [31,32]. Logue and Sattar pointed out that the rea-
sons for this behavior are unknown but it may be that
BMI at diagnosis reflects the underlying pathophysi-
ology, with those diagnosed at lower BMI having either
proportionately greater beta-cell failure, or else a greater
diabetes predisposition via more rapid ectopic fat storage
for a given BMI, factors potentially leading to worse out-
comes [31]. Finally, another potential interference could
stem from diabetes drugs that modulate body weight,
such as insulin, sulfonylureas, and metformin. The per-
centage of individuals utilizing each drug, however, was
not different between individuals with and without
CAD, as illustrated in Table 1. Anyway, the cross-
sectional nature of our data suggest that differences
found in BMI could be due to selection bias rather than
pathophysiologically connected to CAD.
Regarding non-classical cardiovascular risk factors, we
did not find differences between adiponectin levels in
diabetic patients with and without CAD. Accumulating
evidence suggests that higher plasma adiponectin is a sur-
rogate biological marker for better cardiovascular progno-
sis, mainly in patients with low risk of CVD [12]. In
subjects with high risk of CVD, as seen in our present
study group, or in those with established CAD, however,
higher total adiponectin level seems to be associated with
poorer prognosis [33]. A possible explanation is that
higher or neutral levels of adiponectin in the CAD groupmay be a physiological response to limit endothelial dam-
age in the very early stage of the atherogenic process. In
more advanced disease, however, compensatory processes,
including an increase in adiponectin levels, are often su-
perseded [12].
We sought to investigate whether meeting glucose,
blood pressure, and lipid therapeutic goals for adults
with diabetes mellitus could have any effect on the fre-
quency of CAD [14]. At first glance, the small percent-
age of individuals globally meeting the proposed goals
(less than 50%) stands out. Moreover, treatment goals
for cardiovascular risk factors didn’t differentiate be-
tween individuals with or without CAD in the normo-
glycemic group. In those with T2DM, however, an
opposite behavior was seen with HDL and LDL. Less pa-
tients in the CAD-positive group met therapeutic goals
for HDL, as expected. This could be due to HDL being a
risk factor relatively difficult to modify. Besides, the lim-
ited efficacy of statins and fibrates in raising HDL when
compared to their LDL/triglyceride-lowering capabilities
could partly explain this finding. Conversely, T2DM pa-
tients with CAD met LDL treatment goals more fre-
quently than CAD-free individuals. This is probably due
to a higher frequency of statin use.
As we found no differences in major risk factors in
normoglycemic subjects with or without CAD, some hy-
potheses can be discussed. Of note, our normoglycemic
group has been selected by two combined criteria: fast-
ing glucose and HbA1c, selecting thus individuals that
are highly glucose-tolerant. One possible explanation
would be that in a high risk diabetes setting, such as the
one studied, risk factors are potentiated by the occur-
rence of diabetes/hyperglycemia. Another hypothesis
would be statistical error due to the limited sample size.
In this analyses, we did not aim to compare clinical pa-
rameters and risk factors between T2DM subjects and
non-diabetic individuals, given the highly differing meta-
bolic profile of both groups. Our goal was rather to as-
sess risk factors related to the presence of CAD in a
normoglycemic group, verifying if they are similar to
those found in individuals with T2DM.
The major strength of our study was the use of a gold-
standard method to diagnose coronary stenosis. Some
limitations of our study should be discussed. Firstly,
studied individuals are represented by high cardio-
vascular risk subjects, as they had clinical indication for
cardiac catheterization. Therefore, our data are not ap-
plicable to the general T2DM population. On the other
hand, this feature enhances stratification of some ana-
lyses, as, for example, in comparison with our normogly-
cemic group, also with a high cardiovascular risk except
for hyperglycemia. Secondly, the number of subjects
studied is small and results should be interpreted with
caution. Moreover, OGTT were performed in an even
Bittencourt et al. Diabetology & Metabolic Syndrome 2014, 6:46 Page 7 of 8
http://www.dmsjournal.com/content/6/1/46smaller subset of individuals and could not be utilized in
the analyses. Thirdly, the 50% criterion utilized to regard
coronary stenosis as significant could be a potential
source of bias, since thrombotic events can occur in dia-
betic patients in thinner but unstable plaques. Fourthly,
other cardiovascular risk markers such as C-Reactive
Protein have not been assessed. Finally, another import-
ant weakness of this study is its cross-sectional design,
chiefly due to the cumulative effect risk factors can have
with prolonged exposure and the concept of metabolic
memory in the initial treatment period, both analyses
being impossible in our sample.
Conclusions
Patients with T2DM and coronary artery disease assessed
by coronary angiography show higher prevalence of some
non-modifiable classical risk factors such as age, but
others modifiable as worse glycemic control, higher levels
of triglycerides, and lower HDL. Glycemic control was as-
sociated with extension of coronary lesions and severity of
stenosis in individuals with T2DM. This raises the import-
ant question whether a tighter glycemic control, or even
HDL and triglycerides control for that matter, could re-
duce CAD rates and mortality in these patients, at least in
this population displaying high cardiovascular risk but
short diabetes duration comparatively to preceding stud-
ies. Naturally, this intervention must be tested in a pro-
spective design, in populations with the same clinical and
metabolic features as our sample. Further studies are ne-
cessary to evaluate coronary lesions at a functional level.
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